Autologous graft-versus-host disease induction in advanced breast cancer: role of peripheral blood progenitor cells.
Autologous graft-versus-host disease induction in advanced breast cancer: role of peripheral blood progenitor cells.
复制标题
晚期乳腺癌中自体移植物抗宿主病的诱导：外周血祖细胞的作用。
DOI：
10.1054/bjoc.2000.1499
复制
发表时间：
2000
影响因子：
8.8
通讯作者：
Kennedy,MJ
中科院分区：
文献类型：
--
作者：
vanderWall,E;Horn,T;Bright,E;Passos-Coehlo,JL;Bond,S;Clarke,B;Altomonte,V;McIntyre,K;Vogelsang,G;Noga,SJ;Davis,JM;Thomassen,J;Ohly,KV;Lee,SM;Fetting,J;Armstrong,DK;Davidson,NE;Hess,AD;Kennedy,MJ
本研究的目的是探讨使用外周血祖细胞（PBPC）对晚期乳腺癌患者诱导自体移植物抗宿主病（GVHD）的影响。14例IIIB期乳腺癌患者和36例IV期乳腺癌患者在PBPC-T±骨髓移植（BMT）后接受环孢素（CsA）2.5mg/kg ~（-1）iv，d 0-28，干扰素-γ（IFNg）0.025mg/m2 sc，qod，d 7 -28。既往高剂量化疗包括环磷酰胺6 g/m2和塞替派800 mg/m2。在18/50例（36%）患者中诱导了组织学证实的≥ II级皮肤GVHD，并且与造血支持来源无关。体外研究表明，移植后，76%的患者已经产生了针对其自身的移植前PHA-淋巴母细胞的自身细胞毒性。在NK细胞系K562和乳腺癌细胞系T47 D中观察到≥ II级GVHD的发生与细胞溶解之间的显著相关性。中位随访时间为2年半，总生存率（OS）为58%，无病生存率（DFS）为26%，均独立于GVHD的发生，与其他晚期乳腺癌高剂量化疗研究中观察到的结果相似。因此，尚不清楚诱导自体GVHD伴自体细胞毒性淋巴细胞的发生是否可在这组患者中产生抗肿瘤作用。bjcancer。网
The purpose of the present study was to investigate the impact of the use of peripheral blood progenitor cells (PBPCs) on the induction of autologous graft-versus-host disease (GVHD) in patients with advanced breast cancer. 14 women with stage IIIB and 36 women with stage IV breast cancer received cyclosporine (CsA) 2.5 mg kg–1 iv daily, d 0–28, and interferon-gamma (IFNg) 0.025 mg/m2 sc qod, d7–28, following PBPC-T±bone marrow transplantation (BMT). Preceding high-dose chemotherapy consisted of cyclophosphamide 6 g/m2 and thiotepa 800 mg/m2. Histologically proven≥ grade II cutaneous GVHD was induced in 18/50 (36%) of patients and was independent of the source of haematopoietic support. in vitro studies showed that post-transplant, 76% of patients had developed auto-cytotoxicity against their own pre-transplant PHA-lymphoblasts. A significant correlation between the occurrence of GVHD≥ grade II and cytolysis was observed in the NK cell-line K562 and the T47D breast cancer cell-line. With a median follow-up of 2½ years, the overall survival (OS) is 58%, the disease-free survival (DFS) 26%, both independent of the development of GVHD and similar to what has been observed in other studies on high-dose chemotherapy in advanced breast cancer. It therefore remains unclear whether the induction of autologous GVHD with the occurrence of auto-cytotoxic lymphocytes can result in an anti-tumour effect in this group of patients.© 2000 Cancer Research Campaign http://www. bjcancer. com